The psychosocial context surrounding the patient and the psychobiological model do offer interesting perspectives from which to study the placebo response. The term 'response' should only be reserved for an active neurobiological process that occurs as a result of a dummy treatment. The context surrounding the administration of a placebo can also lead individuals to expect a worsening of symptoms; indeed changes in the negative direction are observed as part of the nocebo effect. One way of studying nocebo effects after medical treatment is to analyse the findings of randomised double-blind placebo-controlled trials. The importance of these studies is given by their attempt to maximise the placebo components of therapies and thus to minimise the worsening of symptoms. Assessing situations where loss of placebo mechanisms may require increased therapeutic dosage represents another crucial aspect. These aspects become even more important in patients with dementia, who may exhibit a disruption of the expectancy-evoked placebo-analgesia network and impaired sensory and affective responses to pain. In this chapter we attempt to answer specific questions with regard to patients with cognitive impairment, even though at present we only have a limited understanding of the factors that influence patients' response to pain and to placebo treatment

The role of cognitive impairment in the placebo and nocebo effects

AMANZIO, Martina
2016-01-01

Abstract

The psychosocial context surrounding the patient and the psychobiological model do offer interesting perspectives from which to study the placebo response. The term 'response' should only be reserved for an active neurobiological process that occurs as a result of a dummy treatment. The context surrounding the administration of a placebo can also lead individuals to expect a worsening of symptoms; indeed changes in the negative direction are observed as part of the nocebo effect. One way of studying nocebo effects after medical treatment is to analyse the findings of randomised double-blind placebo-controlled trials. The importance of these studies is given by their attempt to maximise the placebo components of therapies and thus to minimise the worsening of symptoms. Assessing situations where loss of placebo mechanisms may require increased therapeutic dosage represents another crucial aspect. These aspects become even more important in patients with dementia, who may exhibit a disruption of the expectancy-evoked placebo-analgesia network and impaired sensory and affective responses to pain. In this chapter we attempt to answer specific questions with regard to patients with cognitive impairment, even though at present we only have a limited understanding of the factors that influence patients' response to pain and to placebo treatment
2016
An Introduction to Pain and its relation to Nervous System Disorders
John Wiley & Sons, Ltd
Wiley-Blackwell
Capitolo 16
373
386
9781118455913
Expectancy theory, Nocebo effects, Placebo analgesia, Primary dementia, Randomised controlled trials
Amanzio M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1636062
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact